3 of the best ASX 200 stocks to buy in FY25

Big returns and buy ratings. That's what Bell Potter is saying about these shares.

| More on:
Four people gather around laptop and cheer

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new financial year is on the horizon, so what better time to make some new additions to your investment portfolio.

But which ASX 200 stocks could be buys?

Let's take a look at three best buys for FY 2025 according to analysts at Bell Potter. They are as follows:

Bega Cheese Ltd (ASX: BGA)

Bell Potter sees a lot of value in this diversified food company's shares. Particularly given that its outlook is becoming more positive and its shares are trading on historically low forward earnings multiples. It explains:

Our Buy rating remains on BGA is based on: (1) a historically low forward multiple; (2) consolidating milk processing infrastructure; and (3) the material valuation upside should BGA execute on its 5 year targets. In addition, we note that the key drivers of FY25e appear to have improved in recent months, with: (1) Australian milk production continuing to demonstrate YOY growth through 4Q24; (2) YOY gains in SMP pricing in FY25e futures markets; and (3) a material YOY downdraft in farmgate milk prices in FY25e based on minimum opens by major processors.

Bell Potter has a buy rating and $5.35 price target on its shares. This implies potential upside of 26% for investors over the next 12 months.

Neuren Pharmaceuticals Ltd (ASX: NEU)

Another ASX 200 stock that Bell Potter is bullish on for FY 2025 is biotechnology company Neuren Pharmaceuticals.

The broker believes it could be a great long term pick for patient investors. It explains:

In the last six months, NNZ-2591 reported highly encouraging Phase 2 data in two rare diseases. NEU will once again have first-to-market opportunities in these two rare diseases, assuming future Phase 3 trials are successful. While short-term news will continue to be impacted by Acadia's commercialisation of NEU's first drug, called Daybue, we maintain our BUY recommendation for investors who have a longer 2 to 3-year investment horizon.

Bell Potter has a buy rating and $28.00 price target on its shares. This suggests that potential upside of 32% is possible from current levels.

Boss Energy Ltd (ASX: BOE)

If you're not averse to investing in the mining sector, then this uranium miner could be an ASX 200 stock to buy according to Bell Potter.

The broker sees "significant value" in its shares right now. Especially given its geographically diversified multi-asset portfolio and the uranium bull market. It said:

BOE's Honeymoon project recommenced production in April-24, with first sales expected in July-24. The business over the last six months has changed somewhat, with the acquisition of a 30% interest in the Alta Mesa project with JV partner enCore energy in South Texas. We continue to see significant value in BOE, with optionality around expansion at Honeymoon via low-risk and cost regional resources at Jasons and Goulds Dam. With the inclusion of Alta Mesa, BOE boasts a geographically diversified multi-asset portfolio with several growth levers yet to be pulled, heading into a uranium bull market.

Bell Potter has a buy rating and $6.35 price target. This implies potential upside of 54% for investors.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man in a business suit peers through binoculars as two businesswomen stand beside him looking straight ahead at the camera.
Broker Notes

What this expert predicts will be the best-performing ASX sectors in FY25

These sectors could be the ones to watch, according to one expert.

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

Buy this ASX 200 stock for 20% upside and a 6% dividend yield

Looking for big returns? Bell Potter thinks this is the stock to buy.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Broker Notes

These ASX shares could rise 25% to 30%

Big returns could be on offer with these shares according to analysts.

Read more »

Two male professional analysts discuss share price movements shown on the computer screen in front of them, with one pointing to a screen
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

'Obvious buying opportunity': Top broker says beaten-up ASX All Ords stock has 253% upside

Wilsons analysts say the market has misread top-line medical trial results released this week.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Broker Notes

Should you pounce on ResMed shares at around $28?

Here's what top broker Citi says.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »